Answer
There is no clinical experience with Xultophy, insulin degludec or liraglutide in pregnant women, the potential human risk is unknown, and Xultophy should be discontinued if pregnancy is planned or occurs.
Sources for this answer
- Xultophy 100 units/mL + 3.6 mg/mL solution for injectionNovo Nordisk Limited · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 6Document updated
Sources checked